Upload File

erbitux仿單 - ndmctsgh.edu.twerbitux in combination with irinotecan is indicated for the treatment...

  • Home
  • Documents
  • Erbitux仿單 - ndmctsgh.edu.twErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor (EGFR)-expressing metastatic co
3

Upload: others

Post on 25-Mar-2020

1 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: Erbitux仿單 - ndmctsgh.edu.twErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor (EGFR)-expressing metastatic co
Page 2: Erbitux仿單 - ndmctsgh.edu.twErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor (EGFR)-expressing metastatic co
Page 3: Erbitux仿單 - ndmctsgh.edu.twErbitux in combination with irinotecan is indicated for the treatment of patients with epiderma growth factor receptor (EGFR)-expressing metastatic co

Development and Targeting Efficiency of Irinotecan

Preclinical Activity of Nanoliposomal Irinotecan Is ... · Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion Ashish

Sample Front Cover - DTICTaxotere or Erbitux iii)examine the effects of stathmin expression on tumor development and the outcomes of Taxotere, Erbitux on blocking tumorigenesis in

PRODUCT MONOGRAPH IRINOTECAN HYDROCHLORIDE …

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225,

Vulnerability to low-dose combination of irinotecan and ...RESEARCH Open Access Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer Pietro

Erbitux 5 mg/mL - Medicines.org.au · Erbitux 5 mg/mL – Product Information ... and overall survival in RAS wild-type but not RAS mutant subjects ... .3 38.6 (58.8,73.2) (31.7,46.0)

Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon … · Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma Salome Paillas1,

Moda Health Plan, Inc. Medical Necessity Criteria Subject: Erbitux

Clinical studies erbitux

Targeting the p38 MAPK Pathway Inhibits Irinotecan ...cancerres.aacrjournals.org/content/canres/early/2011/01/21/0008-5472... · Targeting the p38 MAPK Pathway Inhibits Irinotecan

AusPAR Attachment 1: Product Information for Erbitux · Web viewAttachment 1: Product information for AusPAR Erbitux; cetuximab; Merck Serono Australia Pty Ltd PM-2012-00340-3-4 Date

Neural Stem Cell-Mediated Delivery of Irinotecan ... Stem CellsTransl Med. 2013 .pdfNeural Stem Cell-Mediated Delivery of Irinotecan-Activating Carboxylesterases to Glioma: Implications

Efficacy of FOLFIRI-3 or other irinotecan-based regimens

Photodynamic Therapy Synergizes with Irinotecan to ...cancerres.aacrjournals.org/content/canres/76/5/1066.full.pdf · Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory

Competitor Analysis: EGF-R Antibodies 2015 - Biosuperiors and Biosimilars of Erbitux

Gene Expression Profiling of the Irinotecan Pathway in ...clincancerres.aacrjournals.org/content/clincanres/11/5/2053.full.pdf · Gene Expression Profiling of the Irinotecan Pathway

Randomized Phase III Trial of Cetuximab Plus Irinotecan vs Irinotecan Alone for Metastatic Colorectal Cancer (mCRC) after Failing Prior Oxaliplatin-based

Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), …clincancerres.aacrjournals.org/content/clincanres/21/5/...Cancer Therapy: Preclinical Activity of MM-398, Nanoliposomal Irinotecan

Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan versus Cetuximab/Bevacizumab in Irinotecan-Refractory Colorectal Cancer LB Saltz, HJ Lenz,

ASSESSMENT REPORT FOR ERBITUX cetuximab Procedure No. … · Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type

PLASMA AND TUMOR PHARMACOKINETICS OF IRINOTECAN …

N20-571S023 Irinotecan Clinpharm · 2017-12-22 · Irinotecan_SE8_s21_finalreview.doc 2 . I. Executive Summary . Irinotecan hydrochloride (CPT-11, CAMPTOSAR) is a prodrug derivative

for ERBITUX. ERBITUX - s3.pgkb.org · PDF fileadverse reactions (including rash, pruritus, and nail changes), ... x Nursing Mothers: Discontinue nursing during and for 60 days following

Gene Expression Profiling of the Irinotecan Pathway in ... · pathway using gene expression data for 24 irinotecan pathway genes in human colorectal neoplastic and normal tissues

Parenteral Drug Delivery Market Trends...(irinotecan hydrochloride) Formulation may realize promise of liposomes and irinotecan in a challenging indication. Notable Approvals: 2015

GPRS 仿真实现及其性能优化

胃適安仿單-Nov · Title 胃適安仿單-Nov Created Date 11/17/2011 4:21:38 PM

Algitab 仿單 (TFDA變更) - TTYeng.tty.com.tw/rwd1181/store/F3/Algitab.pdf · Title Algitab 仿單 (TFDA變更) Created Date 3/22/2018 10:36:08 AM

IMPORTANT: PLEASE READ In patients who cannot tolerate …pi.lilly.com/ca/erbitux-ca-pmi.pdf · You ever had a bad reaction/allergy to ERBITUX or any of the non-medicinal ingredients;

1 ASCO 2010 Neue Daten von Erbitux. 2 ASCO 2010 ERBITUX CRC - Orals #3502 Oral Presentation, Maughan et al., Identification of potentially responsive

Erbitux (cetuximab) label - Accessdata FDA

Irinotecan pharmacokinetic and pharmacogenomic alterations ... · Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck

Irinotecan - Topoisomerase Poison

ERBITUX - Navigating Cancer